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Background/aim: Sjögren’s syndrome is a systemic, autoimmune disease and can affect many organs and systems. In this study, we
aimed to evaluate the respiratory manifestations, and the association between interstitial lung disease (ILD) and disease activity in
primary SS (pSS) patients.
Materials and methods: The study design was retrospective cross-sectional, and 151 patients followed up with a diagnosis of pSS
between 2004 and 2019 were included in the study. Demographic and clinical data, laboratory results, chest radiographs and thorax
computed tomography (CT) results were obtained from patient files and hospital imaging system. Thorax CT was requested from all
patients with respiratory complaints and abnormalities in physical examination and pulmonary function test. Disease activity was
calculated with EULAR pSS disease activity index (ESSDAI) and clinical European League Against Rheumatism SS Disease Activity
Index (clin-ESSDAI).
Results: In our study, 97% of pSS patients were female, and the mean age was 55.9 ± 12 years, disease onset age was 45.5 ± 12.1
years, disease duration was 10.7 (1–38) years. According to CT findings of 120 patients, 35% had nodules, and 13.3% had ILD (62.5%
nonspecific interstitial pneumonia, 25% lymphocytic interstitial pneumonia, 12.5% usual interstitial pneumonia). Bronchiectasis,
emphysema, sequelae fibrotic changes, and pleural thickening was found in 3.3%, 5.8%, 15.8%, and 1.7% of patients, respectively.
It was observed that there was a significant relationship between the presence of ILD and persistent cough, mediastinal LAP, low DLCO,
high ESSDAI and clin-ESSDAI scores reflecting disease activity.
Conclusion: The most common pulmonary manifestation in our patients was ILD. ILD was observed more frequently in patients
with moderate and severe disease activity. Some of the ILD patients were diagnosed while they were asymptomatic. Even if they are
asymptomatic, it is important to follow up the patients with physical examination, spirometry, DLCO and thorax CT.
Key words: Sjögren’s syndrome, lung, interstitial lung disease

1. Introduction
Primary Sjögren’s syndrome (pSS) is a systemic,
autoimmune disease characterized by lymphoplasmacytic
infiltration of exocrine glands [1]. Pulmonary involvement
affects 9%–12% of patients; however, with bronchoalveolar
lavage, pulmonary function tests and computed
tomography (CT) data, it is seen that 75% of the patients are
affected in the last period [2]. Although the most common
pulmonary involvement is airway abnormalities in pSS,
interstitial pneumonias are also common [3]. Pulmonary
hypertension and pleural effusion are also among the
conditions that can be seen, but it is less frequently seen
than other connective tissue diseases [4–6]. Pulmonary
involvement is a condition that significantly affects the
quality of life. In this study, we aimed to present the

respiratory manifestations of pSS patients we followed up
in our outpatient clinic. In addition, clinical and laboratory
parameters, including respiratory manifestation, were
compared according to disease activity.
2. Materials and methods
The study design was retrospective cross-sectional, between
January 2020 and June 2020. Patients who were followed up
with the diagnosis of pSS in our outpatient clinic between
2004 and 2019 were included in the study. The data of 151
patients who were diagnosed with pSS according to the
classification criteria of the European-American consensus
group [7]. Clinical, demographic, laboratory findings,
the drugs and pulmonary function tests [spirometry
and diffusing capacity of the lungs for carbon monoxide
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(DLCO)] were examined from their files. Chest radiographs
and thorax CT results were accessed via hospital imaging
system. The study was retrospective, and chest X-ray of all
patients was evaluated by a rheumatologist during their
outpatient follow-up, and tomography was not requested
from patients who did not have respiratory complaints and
whose physical examination and pulmonary function tests
(forced vital capacity (FVC) > 80, forced expiratory volume
in one second (FEV1) > 80, DLCO > 80 ) were normal.
Thus, thorax CT results of 120 patients were obtained. All
thorax CTs were evaluated by a radiologist specialized
in lung imaging. Disease activity was calculated with
EULAR pSS disease activity index (ESSDAI) [8] and
clinical European League Against Rheumatism Sjögren’s
Syndrome Disease Activity Index (clin-ESSDAI) [9]. In
some patients, because the diagnosis of interstitial lung
disease (ILD) was made before the diagnosis of pSS,
disease activities were evaluated during the study period,
not at the time of ILD diagnosis. The study was performed
according to the Declaration of Helsinki.
2.1 Statistical analysis
Statistical evaluation was performed with IBM SPSS
20.0 (IBM Corp., Armonk, NY, USA) package program.
Compliance with normal distribution was evaluated with
Kolmogorov–Smirnov and Shapiro–Wilk tests. Numerical
variables were given as mean ± standard deviation
and median (min-max), and categorical variables as
percentages. Differences between groups were determined
by independent sample t-test and ANOVA for numerical
variables with normal distribution, and Mann–Whitney U
and Kruskal–Wallis tests for numerical variables that do
not have normal distribution. Binary logistic regression
analysis was used to determine the factors affecting the
variable of interest. Relationships between categorical
variables were evaluated using chi-square analysis. In
the test of two-sided hypotheses, p <0.05 was considered
statistically significant.
3. Results
The mean age of 151 pSS patients (97% of the patients were
women) was 55.9 ± 12 years, the mean disease onset age
was 45.5 ± 12.1 years, the mean disease duration was 10.7
(1–38) years, and the follow-up period was 45.8 ± 33.8
months. Fever was present in 5.3% of the patients, weight
loss in 7.9%, and night sweats in 1%. A total of 88.1% of
the patients had dry mouth, 86.1% had dry eyes, 16.6%
had parotitis, 28.5% had arthritis, 19.9% had Raynaud
phenomenon, 29.1% had lymphadenopathy (LAP), 20.5%
had smoking, 22.5% had hypergammaglobulinemia
(hyperIgG), 9.3% had malignancy and 72% had decreased
uptake and excretion in salivary gland scintigraphy.
Salivary gland biopsy confirmed the diagnosis in 66.1% of

patients. The Schirmer test was positive in 82.2% of patients,
rheumatoid factor (RF), antinuclear antibody (ANA), anti
SS-A and anti SS-B antibodies were 65.2%, 90.7%, 62.3%,
50.3%, respectively. Smoking rate among the patients was
20.5%. The effect of smoking on clinical data and thorax CT
results were evaluated. A significant relationship was found
between smoking and the development of emphysema (p
= 0.001). The rate of persistent cough was significantly
higher in smokers as expected (p = 0.013). Since 31
patients did not have thorax CT results, all analyzes except
the general information given above were performed on
120 patients and presented. When the thorax CT results
of 120 patients were reviewed, no finding was observed in
27.5% of the patients. At least one symptom was present in
72.5% of the patients.
According to the CT findings, 35% had nodules in the
lung. The size of the nodules was less than 1 cm and the
patients were followed for the nodule size progression.
Hilar and subcarinal lymph nodes were present in 12.5%
of the patients, and their sizes ranged from 5 mm to 15
mm. Bronchoscopy was performed for mediastinal LAP
in 2 patients, and the results of bronchoscopic biopsy were
evaluated as reactive changes. Two patients had lung cancer
(CA), and they died. Pulmonary manifestations according
to thorax CT and spirometry results of pSS patients are
shown in Table 1.
Cough and shortness of breath were observed in 13.8%
of the patients with respiratory manifestation. ILD was
detected in 75% of symptomatic patients. According to
the results of thorax CT, ILD was detected in 13.3% of
the patients. Lung biopsy is generally not recommended
in pSS patients with ILD, as HRCT and histopathological
findings are well correlated [10]. Therefore, the diagnosis
of ILD was made according to CT results. The follow-up
period of ILD patients was 4.16 ± 3.5 years. The patients
were diagnosed with ILD 4 ± 3.1 years after the diagnosis
of pSS. A total of 31.3% of the patients were diagnosed
with ILD before the diagnosis of pSS.
Smoking history was in 12.5% of ILD patients and
persistent cough in 43.8%. All patients with ILD received
steroid (0.5–1 mg/kg/daily) therapy for a short time. Two
patients received cyclophosphamide (6 cycles/monthly)
therapy for active alveolitis, and azathioprine (AZA) was
used as maintenance therapy for 7 years. While 9 patients
were treated with AZA (1.5–2 mg/daily), and one treated
with mycophenolate mofetil (MMF) (2 g/daily) for eight
years. One patient received Rituximab (RTX) treatment
(two 1000 mg doses, 15 days apart/ every 6 months) for
three years due to an increase in interstitial involvement
under AZA treatment.
When we evaluated the ESSDAI activity scores, it was
seen that 65.8% of our patients had low disease activity,
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Table 1. Respiratory manifestations according to thorax CT and spirometry results of pSS patients.
n: 120

n (%)

Nodule

42 (35)

Mediastinal LAP

15 (12.5)

Interstitial Lung Disease
NSIP
LIP
UIP

16 (13.3)
10 (62.5)
4 (25)
2 (12.5)

Bronchiectasis

4 (3.3)

Segmental atelectasis

7 (5.8)

Emphysema

7 (5.8)

Sequela fibrotic change

19 (15.8)

Tuberculous sequel

2 (1.7)

Airway disease

4 (3.4)

Lung cancer

2 (1.7)

Pleural effusion

2 (1.7)

COPD

2(1.7)

pSS: primary Sjögren’s syndrome, LAP: lymphadenopathy, NSIP: nonspecific interstitial pneumonia, LIP: lymphocytic
interstitial pneumonia, UIP: usual interstitial pneumonia, COPD: chronic obstructive pulmonary disease.

25.8% had moderate disease activity, and 8.3% had
high disease activity. When the patients were evaluated
according to disease activity levels, a significant statistical
difference was observed in patients with ILD, respiratory
manifestations and, mediastinal LAP. In particular, 70%
of patients with high disease activity had ILD, and this
rate was 25.8% in patients with moderate disease activity
and 1.3% in patients with low disease activity. Respiratory
manifestations were observed to be higher in patients with
moderate and high disease activity. However, it should be
kept in mind that not all respiratory manifestations may
be associated with pSS (such as lung cancer, tuberculous
sequel). It was observed the disease onset age of the
patients with low disease activity was lower than the
patients with moderate and high disease activity. There was
no difference in the duration of the disease and the mean
age of the patients in all three activity groups. Comparison
of clinical, demographic and laboratory findings according
to disease activity is presented in Table 2.
Patients with pSS with and without ILD were compared
according to their clinical and laboratory findings. All
patients with ILD were women. The mean ages and disease
duration were similar in both groups. Persistent cough was
significantly higher in patients with a diagnosis of ILD.
Mediastinal LAP was higher in patients with ILD than in
patients without ILD. Malignancy development was found
to be higher but not statistically significant in patients with
a diagnosis of ILD.
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ESSDAI and clin-ESSDAI scores were evaluated in both
groups in terms of the disease activity. ESSDAI and clinESSDAI scores of patients with interstitial lung disease were
significantly higher than the group without ILD (p = 0.000)
(Figure). When the respiratory function tests of both groups
were compared, it was seen that the DLCO test results were
significantly lower in patients with ILD (p = 0.028), and the
difference between FVC and forced expiratory volume in 1
s (FEV1)/FVC results were not statistically significant. Both
groups did not differ from each other in terms of mean age
and duration of disease. Two patients with pulmonary arterial
hypertension (PAH) were in the non-ILD group. The data of
patients with and without ILD are compared in Table 3.
In the logistic regression analysis performed to determine
the risk factors affecting the presence of ILD, it was observed
that there was a significant relationship with persistent cough,
mediastinal LAP, low DLCO, high ESSDAI and clin-ESSDAI
scores reflecting disease activity. In the multivariate analysis,
a significant relationship was found only between high clinESSDAI scores and the presence of ILD (Table 4).
Laboratory and clinical findings of 16 patients with ILD were
presented in Table 5, but statistical analysis could not be
performed due to the small number of patients in the subgroups.
FVC and DLCO values were found to be better in lymphocytic
interstitial pneumonia (LIP) subgroup than other subgroups
in ILD. The ESSDAI and clin-ESSDAI score were higher LIP
and usual interstitial pneumonia (UIP) patients compared to
nonspecific interstitial pneumonia (NSIP) patients (Table 5).
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Table 2. Comparison of data according to disease activity.

n (%)

Low
(n: 79)

Moderate
(n: 31)

High
(n: 10)

p

Age (mean±std)

55.7±11.85

61.77±11.04

59±14.4

0.054͌

Disease onset age

44.91±12.18

51.43±11.76

48.92±12.84

0.038͌

Disease duration

129.38±67.12

124.16±65.37

121±50.60

0.886͌

Smoking

17(25)

11(35.5)

0

NA

Dry mouth

66(83.2)

28(90.3)

10(100)

0.278

Dry eyes

69(86.1)

28(90.3)

9(90)

0.807

Vasculitis

3(3.8)

2(6.5)

1(10)

0.636

Neuropathy

0

4(12.9)

4(40)

NA

Myositis

0

1(3.2)

1(10)

NA

Parotitis

14(17.7)

5(16.1)

2(20)

0.958

Raynaud phenomenon

13(16.5)

9(29)

1(10)

0.239

Respiratory manifestations

49(62)

29(93.5)

9(90)

0.002

Mediastinal LAP

7(8.9)

4 (12.9)

4(40)

0.003

ILD

1(1.3)

8 (25.8)

7(70)

0.000

LAP

24(30.4)

7(22.6)

6(60)

0.083

Malignancy

7(8.9)

6(19.4)

1(10)

0.300

ANA (+)

72 (91.1)

28(90.3)

9(90)

0.987

Anti SS-A antibody

53(67.1)

16(51.6)

6(60)

0.316

Anti SS-B antibody

42(53.2)

12(38.7)

6(60)

0.317

HyperIgG

20(25.3)

6(19.4)

5(50)

0.154

Hypocomplementemia

10(15.6)

3(10.7)

0

NA

͌ Anova, LAP: lymphadenopathy, ILD: interstitial lung disease, ANA: antinuclear antibody, hyperIgG: hypergammaglobulinemia, NA:
not available.
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Table 3. Clinical and laboratory data of pSS patients with and without ILD.

n (%)

pSS with ILD
n: 16

pSS without ILD
n: 104

p

Age (mean ± std)

60.4 ± 11.3

55.7 ± 12.3

0.167 T

Disease duration (mean ± std)

10.3 ± 6

10.7 ± 5.4

0.824 T

Disease onset age (mean ± sd)

50.2 ± 9.9

45.3 ± 12.2

0.147 T

DLCO

60.1 ± 20.4

75 ± 15.1

0.028 T

FVC

87.9 ± 22.8

92.9 ± 19.2

0.232 T

FEV1/FVC

103.3 ± 16.2

105.2 ± 12.3

0.495 T

ESSDAI *

13 (5–28)

1 (0–19)

0.000͌

Clin-ESSDAI *

14.5 (5–31)

0 (0–22)

0.000 ͌

Smoking

2 (12.5)

26 (28)

0.233

Cough

7 (43.8)

16 (15.4)

0.014

Dry mouth

14 (87.5)

90 (86.5)

1

Dry eyes

13 (81.3)

92 (88.5)

0.421

Vasculitis

1 (6.3)

5 (4.8)

0.585

Raynaud

4 (25)

19 (18.3)

0.506

Parotitis

2 (12.5)

19 (18.3)

0.735

Mediastinal LAP

6 (37.5)

9 (8.7)

0.005

Malignancy

4 (25)

10 (9.6)

0.092

ANA (+)

15 (93.8)

94 (90.4)

1

Anti SS-A antibody

10 (62.5)

65 (62.5)

1

Anti SS-B antibody

10 (63)

50 (48.1)

0.421

HyperIgG

5 (31.3)

26 (25)

0.556

PAH

-

2 (1.7)

NA

͌ Mann-Whitney U test used, t Student’s t-test, * Since the data are not normally distributed, median (min-max)
values are given. DLCO: diffusing capacity of the lungs for carbon monoxide, FVC: forced vital capacity, FEV1/FVC:
forced expiratory volume in 1 s/forced vital capacity, ANA: antinuclear antibody, ILD: interstitial lung disease, LAP:
lymphadenopathy, ESSDAI: EULAR primary Sjögren’s syndrome disease activity ındex, clin-ESSDAI: clinical European
League Against Rheumatism Sjögren’s Syndrome Disease Activity Index, hyperIgG: hypergammaglobulinemia, PAH:
pulmonary arterial hypertension, NA: not available.
Table 4. Factors affecting ILD according to the logistic regression model.
Univariate

Multivariate

OR (%95CI)

p

Cough

4.28 (1.39–13.14)

0.011

Mediastinal LAP

6.33 (1.87–21.48)

0.003

DLCO

0.96 (0.919–0.998)

0.041

ESSDAI

1.42 (1.23–1.63)

0.000

Clin-ESSDAI

1.41 (1.22–1.63)

0.000

OR (%95CI)

p

1.51 (1.19–1.91)

0.001

LAP: lymphadenopathy, DLCO: diffusing capacity of the lungs for carbon monoxide ESSDAI: EULAR primary Sjögren’s
syndrome disease activity ındex, clin-ESSDAI: clinical European League Against Rheumatism Sjögren’s Syndrome
Disease Activity Index.
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Table 5. Clinical and laboratory findings of ILD subgroups patients.

n (%)

NSIP
(n = 10)

LIP
(n = 4)

UIP
(n = 2)

Age

61.5 ± 11.8

58 ± 12.9

68 ± 2.7

Disease duration

9.2 ± 7.2

11.8 ± 3

12.9 ± 1.3

Disease onset age

52.3 ± 10.1

46.2 ± 10.3

55.1 ± 14

Dry mouth

9 (90)

3 (75)

2 (100)

Dry eyes

8 (80)

3 (75)

2 (100)

Raynaud

3 (30)

1(25)

-

Parotitis

1 (10)

-

1 (50)

Arthritis

1 (10)

3 (75)

1 (50)

ANA positivity

9 (90)

4 (100)

2 (100)

Anti SS-A antibody positivity

5 (50)

4 (100)

1 (50)

Anti SS-B antibody positivity

5 (50)

4 (100)

1 (50)

Cough

4 (40)

1 (25)

2 (100)

Smoking

2 (20)

-

-

Malignancy

3 (30)

-

1 (50)

HyperIgG

2 (20)

2 (50)

1 (50)

ESSDAI

10 (5–15)

21 (13–28)

18(15–21)

Clin-ESSDAI

12(5–18)

22 (15–31)

19.5 (17–22)

FVC

85(61–146)

94 (88–107)

65(60–70)

DLCO

58(40–84)

76(69–84)

58(50–65)

NSIP: nonspecific interstitial pneumonia, LIP: lymphocytic interstitial pneumonia, UIP: usual interstitial pneumonia, HT:
hypertension; ANA: antinuclear antibody, ILD: interstitial lung disease; hyperIgG: hypergammaglobulinemia, ESSDAI:
EULAR primary Sjögren’s syndrome disease activity index, FVC: forced vital capacity, DLCO: diffusing capacity of the lungs
for carbon monoxide, clin-ESSDAI: clinical European League Against Rheumatism Sjögren’s Syndrome Disease Activity
Index.

4. Discussion
In our study, the respiratory complaints and the
respiratory manifestations detected by imaging methods
of pSS patients followed up in our outpatient clinic, and
the relationship between these findings (especially ILD)
with disease activity score were presented. The respiratory
manifestation that we observe in Sjögren’s syndrome
are varied, and not all of these findings are related to
disease and disease activity. However, ILD is associated
with disease activity. In the literature, the incidence
of respiratory manifestations is estimated to be 10% 1
year after the diagnosis of Sjögren’s syndrome, and the
rate rises to 20% after 5 years [11]. Our ILD patients
were diagnosed 4 ± 3.1 years after the diagnosis of pSS
is consistent with the literature. A total of 31.2% of ILD
patients were diagnosed when they were asymptomatic,
so it is important to evaluate patients with examination,
spirometry, DLCO and imaging methods, even if they

are asymptomatic. The respiratory manifestations were
evaluated separately, regardless of their relationship
with disease activity.
In 7.1% of the pSS patients, shortness of breath was
the reason for admission to the outpatient clinic. The
rate of persistent cough among patients was 19.2%. The
persistent cough rate has been reported as 41%–61% in
patients with Sjögren’s syndrome [12], but this rate was
found to be significantly lower in our study. However,
persistent cough was significantly higher in the ILD
group. The reasons might include airway involvement,
bronchial inflammation, abnormal mucociliary
clearance, gastroesophageal reflux [13].
Nodules were detected in 23% of the patients
in thorax CT. It is known that bronchial mucosaassociated lymphoid tissue (BALT) lymphoma [14]
and pulmonary amyloidosis [15] may have nodular
appearance in the lung parenchyma. Therefore,
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patients are followed up in terms of increase in nodule size
and nature.
Mediastinal LAP may be related to follicular bronchiolitis,
interstitial lung disease, and pulmonary lymphoma [13].
Mediastinal lymphadenopathies were observed more in
patients with interstitial lung disease and high disease activity
score in our study. The high disease activity in most of the ILD
patients also overlaps with this situation. Bronchoscopy was
performed in 2 cases due to increased LAP size and the biopsy
results were reported as benign changes.
Most of our patients had low disease activity and
it was observed that patients with low disease activity
were younger. It was thought that the patients who were
diagnosed and treated at an earlier age, and who were
regularly followed-up in the outpatient clinic have lower
disease activities in the long term, although they had similar
disease durations due to better disease control.
Malignancy development was found to be higher in
patients with a diagnosis of ILD. ESSDAI and clin-ESSDAI
scores of patients with ILD were significantly higher than
the group without ILD (p = 0.000). Due to the relationship
of ILD with disease activity and the heavy burden of disease,
the rate of malignancy was considered to be high. According
to a meta-analysis, hospital-based studies showed higher
RRs for malignancy than population-based studies. It is
thought that hospitalized patients with pSS have more
severe disease which suggests that more severe pSS is higher
probability of malignancy due to disease burden [16].
Interstitial lung disease was detected in 13.3 % of our
patients, and the vast majority of them were in the NSIP
pattern that supports the literature [17]. Although there are
studies showing that pSS patients with ILD are older than
patients without ILD [18–20], in our study, there was no
significant difference between both groups in terms of the
mean age (p = 0.167), and disease duration (p = 0.824).
Some studies also reported that older age at disease onset
and longer disease duration were associated with a higher
risk of pulmonary involvement in pSS [21,22]. In our study,
the ILD group had significantly older disease onset, but no
significant relationship was found in the logistic regression
analysis. In ILD subgroups, it was observed that UIP patients
were older, had older disease onset and longer disease
duration. Also, the patients with UIP had higher disease
activity. ESSDAI and clin-ESSDAI scores were higher in the
UIP and LIP groups than in the NSIP group. There was no
significant difference between ILD subgroups in terms of
pulmonary domain of ESSDAI. In addition, when we look
at the pulmonary domain of ESSDAI scores of patients with
ILD, it was observed that 87% had moderate activity and
13% had high activity.
The course of the disease in the NSIP pattern may be
uncertain [23]. Due to the diagnosis of NSIP, 40% of the
patients received AZA, 10% CyC, 10% MMF and shortterm steroid treatment. Steroids are generally recommended
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for NSIP patients [13]. The mean follow-up period was
2.9 ± 2.83 years. A total of 50% of the NSIP patients were
diagnosed with ILD before the diagnosis of pSS. Studies
showing that the use of AZA, CyC and RTX in the treatment
of NSIP support our data [13].
LIP is the most characteristic of pSS and is marked by
lymphoplasmacytic infiltration tissue (such as interstitium,
alveolar space) and lymphoid aggregates. A polyclonal or
monoclonal gammopathy may be observed in ILD patients
and LIP can be a precursor to a BALT lymphoma [24].
Patients are followed more carefully in this respect. In our
study, LIP patients accounted for 25% of all ILD cases. LIP
patients consisted of younger patients and earlier onset
of disease compared to other ILD subgroups. The mean
follow-up period was 6.7 ± 4.5 years. Although LIP patients
have moderate disease activity in terms of the ESSDAI
pulmonary domain, ESSDAI score have been found to be
high due to the lymphoid load they carry, with the effect
of the extra pulmonary domains. When these patients were
diagnosed with LIP, they were asymptomatic in terms of
respiratory findings. All LIP patients received steroid and
they used AZA for extra pulmonary involvement.
Restrictive ventilation defect is seen in pulmonary
function tests of pSS-ILD patients [25]. Spirometry might
be done early after disease onset, even in asymptomatic
patients. The reduction in DLCO appears to be the most
common abnormality in ILD [13]. In the early phase of
ILD, a preserved FVC is observed with a decrease in DLCO.
DLCO is more sensitive in predicting the presence of ILD,
FVC may be more useful when assessing the extent of the
disease [26]. Although FVC was lower in the ILD group
than non-ILD in our study, no statistical significance was
observed. However, DLCO was significantly lower in the
ILD group (p = 0.028). DLCO was lower in ILD subgroups,
especially in NSIP and UIP groups.
Studies have shown that there is an association between
ILD and ANA, anti SS-A , anti SS-B antibodies positivity
positivity, hyperIgG, RF positivity and lymphopenia [27,
19, 20]. In our study, there was no significant relationship
between ILD and ANA, anti SS-A , anti SS-B antibodies,
and RF positivity (not evaluated as titer). In addition, there
was no significant difference between the patients with and
without ILD in terms of hyperIgG.
The number of patients with airway abnormalities (3%)
and chronic obstructive pulmonary disease (COPD) (1%) in
our study was quite low. Although the airway abnormality
as the most common finding of pulmonary involvement
in pSS patients [12], the most common involvement in
our study was ILD. Airway abnormality is associated with
destruction or cellular infiltration of exocrine glands in
pSS, and trachea and bronchi are also affected [12]. It can
be difficult to understand whether the airway abnormality
is due to in pSS or is due to some other reason, such as
smoking. Although it has been shown in some studies
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conducted with pSS patients that the incidence of COPD
increased 1.4 times compared to the general population, such
a result was not obtained in our study [28].
PAH is an important and severe complication, which is
encountered in many collagen tissues disorders. There are
case reports [29, 30] on the presence of PAH in pSS and one
study [31] using echocardiography. In our study, 2 patients
were diagnosed with PAH by right heart catheterization.
In addition, in 2 patients, pulmonary systolic pressure
measured assessment only with echocardiography, and it was
found 35 mmHg. For that reason, the latest two patients were
not included in the statistical analyses in term of PAH. All of
these four patients had no ILD.
The limitations of our study were its retrospective design,
small sample size, and short follow-up time. Due to the small
number of ILD patients, statistical analysis could not be
performed on ILD subgroups. The strength of the study was
that the physical examination, spirometry, DLCO and thorax
CT results of 120 pSS patients were performed in a single
center and by experts in the field. In addition, the scarcity of
studies evaluating the relationship between disease activity
and ILD makes this study important. Although disease
activity was low in most of our patients, the activity level was

found to be high in ILD patients. More studies are needed
on the relationship between disease activity and organ
involvement.
5. Conclusion
Respiratory manifestations are seen more frequently in pSS
with the effect of innovations in imaging methods. Pulmonary
involvement is a condition that significantly affects the
quality of life. Especially, ILD is an important cause of
morbidity and mortality in pSS. Early diagnosis is important.
The fact that most of the patients with radiological findings
are asymptomatic and even some of the patients diagnosed
with ILD are asymptomatic have shown us the importance
of physical examination, spirometry, DLCO, chest X-ray and,
if necessary, tomography. Patients should be informed about
long-term regular follow-up and treatment compliance.
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